New Practitioner Network

 View Only
Back to discussions
Expand all | Collapse all

đź“ŁGLP-1s: Beyond Diabetes - New Indications You Need to Know!

  • 1.  đź“ŁGLP-1s: Beyond Diabetes - New Indications You Need to Know!

    Posted 21 days ago

    Hey New Practitioners! 

    The therapeutic horizon for GLP-1 receptor agonists is expanding rapidly! To ensure you're providing the best patient care, it's crucial to stay informed about emerging indications. 

    • NASH Breakthroughs: Several GLP-1 agonists are in development for Non-Alcoholic Steatohepatitis (NASH). Specifically, efinopegdutide is currently being studied to demonstrate reduction in liver fat compared to placebo. 

    • Cardiovascular Protection: Beyond Glucose Control: Research increasingly supports GLP-1s for cardiovascular benefits, even in patients without diabetes. The SELECT trial investigates reduction in cardiovascular complications with semaglutide in patients with obesity and established cardiovascular disease. 

    • OSA (Obstructive Sleep Apnea) Exploration: Emerging research is investigating the potential of GLP-1s to reduce AHI (Apnea-Hypopnea Index) in patients with OSA and obesity. Tirzepatide is currently being studied to demonstrate a reduction in AHI scores.  

    • Alzheimer's Disease: A Novel Target?: Early-stage research suggests GLP-1s might offer neuroprotective benefits. Semaglutide is being studied in patients with early-stage Alzheimer's, exploring its impact on cognitive function and amyloid plaque burden.  

    • Additional indications under investigation: Osteoarthritis (OA) of knee in obesity, diabetic retinopathy, diabetic nephropathy in T2DM and CKD, peripheral artery disease (PAD) in T2DM, chronic heart failure in obesity

    Don't miss out on these game-changing developments! Staying informed ensures you can provide cutting-edge care for your patients. 

    #GLP1 #NASH #Cardiovascular #Diabetes #OSA #Alzheimers #Neuropathy #NewPractitioner #Pharmacy #ClinicalTrials #APhA #ContinuingEducation 

    💡Drop in comments for which of these emerging GLP-1 indications excites you the most, and why?🗣️



    ------------------------------
    Joanne Shen
    Education Standing Committee
    ------------------------------


Related Content